Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ENROLLMENT NOW COMPLETED FOR OPUS-1, OPUS-2 AND OPUS-3 PHASE 3 TRIALS EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS

VAXCYTE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN CARLOS, CALIF., APRIL 07, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON TUESDAY, APRIL 14, 2026 AT 2:15 P.M. ET / 11:15 A.M. PT.

VAXCYTE TO PRESENT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

OPUS-1 PHASE 3 STUDY DESIGNED TO ESTABLISH A NEW STANDARD FOR ADULT PNEUMOCOCCAL CONJUGATE VACCINES (PCVS) THROUGH HEAD-TO-HEAD SAFETY, TOLERABILITY AND IMMUNOGENICITY COMPARISONS OF VAX-31 WITH CAPVAXIVE (PCV21) AND PREVNAR 20 (PCV20), THE CURRENT STANDARD-OF-CARE PCVS

VAXCYTE COMPLETES ENROLLMENT OF OPUS-1 AND OPUS-2 PHASE 3 TRIALS EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS

BASED ON THE STRENGTH OF UNPRECEDENTED RESULTS FROM THE POSITIVE PHASE 1/2 STUDY IN ADULTS AGED 50 AND OLDER, VAXCYTE ADVANCED VAX-31 HIGH DOSE INTO COMPREHENSIVE PHASE 3 ADULT PROGRAM; TOPLINE DATA FROM THE OPUS-1 PIVOTAL NONINFERIORITY TRIAL EXPECTED IN THE FOURTH QUARTER OF 2026

POSITIVE VAX-31 PHASE 1/2 ADULT DATA PUBLISHED IN THE LANCET INFECTIOUS DISEASES HIGHLIGHT BEST-IN-CLASS POTENTIAL OF VAXCYTE'S 31-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) CANDIDATE

COMPREHENSIVE VAX-31 ADULT PHASE 3 CLINICAL PROGRAM, FINALIZED IN CONSULTATION AND ALIGNMENT WITH FDA, ADVANCES WITH THREE PHASE 3 STUDIES UNDERWAY TO SUPPORT PLANNED BLA SUBMISSION TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM OPUS-1 EXPECTED IN FOURTH QUARTER OF 2026; OPUS-2 AND OPUS-3 RESULTS EXPECTED IN FIRST HALF OF 2027 ENROLLMENT COMPLETED IN VAX-31 INFANT PHASE 2 DOSE-FINDING STUDY; TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PRIMARY IMMUNIZATION SERIES AND BOOSTER DOSE EXPECTED EITHER SEQUENTIALLY OR TOGETHER BY END OF FIRST HALF OF 2027 COMPANY ADVANCING EARLY-STAGE PIPELINE, EXPECTS TO INITIATE PHASE 1 ADULT CLINICAL STUDY FOR VAX-A1, A VACCINE CANDIDATE TO PREVENT GROUP A STREP, IN 2026 COMPANY ADVANCES GLOBAL AND U.S. MANUFACTURING CAPABILITIES TO SUPPORT COMMERCIALIZATION OF PNEUMOCOCCAL CONJUGATE VACCINES WITH COMPLETION OF DEDICATED LONZA FACILITY AND INITIATION OF NORTH CAROLINA FILL-FINISH LINE BUILDOUT APPROXIMATELY $2.4 BILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DECEMBER31, 2025 ; EXCLUDES APPROXIMATELY $600.2 MILLION IN NET PROCEEDS FROM FEBRUARY 2026 EQUITY OFFERING COMPANY TO HOST WEBCAST/CONFERENCE CALL TODAY AT 4:30 P.M. ET / 1:30 P.M.

VAXCYTE REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

COMPANY EXPECTS TO REPORT TOPLINE DATA FROM OPUS-3 TRIAL AND OPUS-2 PHASE 3 TRIAL EVALUATING CONCOMITANT ADMINISTRATION OF VAX-31 AND A SEASONAL INFLUENZA VACCINE IN FIRST HALF OF 2027

VAXCYTE DOSES FIRST PARTICIPANTS IN OPUS-3 PHASE 3 TRIAL EVALUATING VAX-31 IN ADULTS PREVIOUSLY VACCINATED WITH LOWER-VALENCY PNEUMOCOCCAL VACCINES

SAN CARLOS, CALIF., FEB. 10, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, ANNOUNCED TODAY THAT IT WILL REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2025 AND PROVIDE A BUSINESS UPDATE AFTER MARKET CLOSE ON FEBRUARY 24, 2026. COMPANY MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST BEGINNING AT 4:30 P.M. ET / 1:30 P.M. PT.

VAXCYTE TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON FEBRUARY 24, 2026

SAN CARLOS, CALIF., FEB. 05, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT IN NEW YORK ON THURSDAY, FEBRUARY 12, 2026 AT 1:30 P.M. ET / 10:30 A.M. PT.

VAXCYTE TO PRESENT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT

SAN CARLOS, CALIF., FEB. 02, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, ANNOUNCED TODAY THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 12,650,000 SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $50.00 PER SHARE.

VAXCYTE ANNOUNCES CLOSING OF $632.5 MILLION PUBLIC OFFERING INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

SAN CARLOS, CALIF., JAN. 29, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK. VAXCYTE IS SELLING 11,000,000 SHARES OF COMMON STOCK IN THE OFFERING AT A PUBLIC OFFERING PRICE OF $50.00 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO VAXCYTE FROM THIS OFFERING ARE EXPECTED TO BE $550 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. ALL SHARES OF COMMON STOCK TO BE SOLD IN THE OFFERING WILL BE OFFERED BY VAXCYTE. VAXCYTE HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,650,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

Vaxcyte, Inc.

PCVX

Price

Financial Reports

No items found.

Press Releases

Vaxcyte, Inc.

PCVX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PCVX